A New Dawn for Sight
When 76-year-old Evelyn closed her eyes, the pages of her beloved novels became a blur of indistinct shapes. With advanced dry Age‑related macular degeneration (AMD), her central vision had faded into darkness, robbing her of reading, face recognition, and the simple pleasure of seeing a loved one clearly. Then came the moment the tiny chip was switched on.
In a quiet hospital theatre, surgeons implanted a wafer-thin microchip , about 2 × 2 mm in size and only ~30 microns thick underneath her retina. The chip was part of the PRIMA Bionic Vision System , a radical new approach to restoring sight. In the weeks that followed, Evelyn donned a pair of augmented-reality (AR) glasses linked to a pocket computer. The moment she first recognized a letter on a chart, she describes as “a crack in the darkness.”
The Science of “Seeing Again”
The PRIMA system is unique in its design and ambition. Where previous retinal prostheses required bulky wired connections and offered limited resolution, this one is wireless and uses near-infra-red light to power the implant and deliver visual data.
Here’s how it works:
- AR glasses with a built-in camera capture the scene in front of the patient.
- The pocket processor reduces and translates the visual feed into a simplified data stream.
- The glasses then project infra-red light into the eye, which the implanted chip converts into electrical stimulation of surviving retinal neurons.
- These neurons transmit signals through the optic nerve to the brain, creating percepts of patterns, letters, even words.
- Crucially, the chip is wireless. No trans-scleral cables, no bulky hardware, making the surgical procedure less invasive and safer.
This is more than a gadget, it’s a bold leap toward “seeing again,” not just perceiving light.
Turning the Trial Corner
The clinical trial results released in October 2025 sent ripples through ophthalmology. In a multicenter European study of 38 patients with advanced dry AMD (“geographic atrophy”), 84.4% regained the ability to read letters, numbers and words. Some participants improved by up to 59 letters on a standardized eye chart, a gain equivalent to nearly 10 lines of vision.
Doctors at Moorfields Eye Hospital in London and other center's described it as “a new era in artificial vision.” One surgeon compared it to providing a map where there was once only fog.
What stands out in this trial is not just improvement, but feasibility and stability. Patients retained their peripheral vision, and in follow-ups up to 48 months, no serious device-related decline was reported.
Inside the Operating Room
Implantation of the PRIMA chip takes under two hours, say surgeons. The process involves inserting the microchip into a carefully prepared pocket beneath the retina in the macular region. For the patient, the procedure is typically performed under local or regional anesthesia.
Post-surgery rehabilitation begins with training the visual system to interpret new kinds of stimuli patterns, shapes, lines and gradually progress to letters and words. In Evelyn’s words: “It was like learning to walk again, but for my eyes.”
Why Dry AMD Matters
Dry AMD particularly the form known as geographic atrophy (GA) is one of the leading causes of irreversible vision loss in older adults. Conventional treatments are limited and largely aim at slowing progression rather than restoring vision. For millions around the world, central vision fades while peripheral vision lingers.
PRIMA addresses a desperate need: a way to restore central vision, enabling reading, recognizing faces, and performing tasks previously impossible.
Behind the Breakthrough
The technology originated at Stanford University under Professor Daniel Palanker, who pioneered the idea of a solar-powered microchip under the retina. The device was later developed by Pixium Vision of France and is now managed by Science Corporation in the U.S.
The journey from concept to clinic involved years of animal studies, device refinement, and multiple human feasibility trials.
Challenges Ahead
While the results are exhilarating, a number of hurdles remain.
- The level of vision restored is meaningful but not yet full normal vision; some patients still struggle with tasks like face recognition.
- Long-term durability, cost, and scaling of the technology remain to be seen.
- The device is still not widely approved commercially; regulatory review must run its course.
- Training and adaptation: Patients must relearn how to see with this system, a process that demands time and effort.
What This Means for Patients
For people like Evelyn, the implant doesn’t just restore a function, it restores a life. Reading a book again. Recognizing a grandchild’s face. Walking into a familiar room without fear.
One trial participant said, “I was an avid bookworm and I wanted that back.” Another described the world as “no longer dark, but full of outlines.”
This is not just about technology, it’s about hope delivered.
Looking Forward
The next few years will determine whether PRIMA becomes standard care. If approved and scaled, it could mark a turning point not just for dry AMD, but for how we treat neuro-degenerative sensory loss.
Miniaturization of electrodes, more advanced image processing, and better machine learning could make future versions sharper and more natural.
As the field moves toward commercialization, the question shifts from “can this work?” to “how widely can this be made available?”
Conclusion: A Vision-Future Emerging
In a world where many treatments aim to delay hopelessness, the PRIMA system offers renewal. A tiny chip beneath the retina, sophisticated glasses, a pocket computer, together they give a window back to a once-bright world.
For millions with dry AMD, the darkness begins to lift. And for medicine, this is a milestone in the journey from repair to restoration, from loss to regained sight.
The bionic eye is no longer science-fiction. It’s here.
0 Comments